发明名称 |
USE OF A CD40:CD154 BINDING INTERRUPTOR TO PREVENT COUNTER ADAPTIVE IMMUNE RESPONSES, PARTICULARLY GRAFT REJECTION |
摘要 |
Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signaling interrupter is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue. |
申请公布号 |
SK156099(A3) |
申请公布日期 |
2000.06.12 |
申请号 |
SK19990001560 |
申请日期 |
1998.05.15 |
申请人 |
BIOGEN, INC.;THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY |
发明人 |
KIRK ALLAN D.;HARLAN DAVID M.;THOMAS DAVID;KAUFFMAN MICHAEL;BURKLY LINDA |
分类号 |
C07D215/52;A61K31/16;A61K31/343;A61K31/443;A61K31/445;A61K31/47;A61K31/57;A61K31/7056;A61K38/00;A61K38/13;A61K38/17;A61K39/395;A61K45/00;A61K45/06;A61P37/06;C07D307/88;C07D498/16;C07H19/052;C07K14/705;C07K16/28;(IPC1-7):A61K39/395 |
主分类号 |
C07D215/52 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|